Abstract 315P
Background
Based on PRIMA and PRIME, Niraparib is approved by FDA and NMPA for first-line maintenance of OC regardless of biomarker status. Niraparib is widely used in China, while its efficacy and safety in real world remains to be verified. The purpose of this study was to evaluate the efficacy and safety of niraparib as maintenance in newly diagnosed advanced OC.
Methods
We retrospectively collected patients with pathologically confirmed diagnosis of OC, who received niraparib as first-line maintenance therapy at the Department of Gynecology, Tianjin Cancer Hospital between January 2021 and December 2022. Demographics, baseline characteristics, clinical outcomes and adverse events were collected. The history of niraparib use, including the time from the end of chemotherapy to the start of maintenance therapy, the starting dose, and the stable dose used after 3 months, were also collected.
Results
102 patients were enrolled. The median age was 58 years and 84.3% were FIGO stage III/IV. 18.6% BRCAmut, 58.8% BRCAwt and 22.5% BRCAunkown, while 36.3% HRD deficient, 12.7% HRD proficient and 51% HRD unkown. 53.9% received NACT, 76.5% were R0 after surgery and 62.7% were CR after chemotherapy. Median follow-up was 10.5m. In the ITT population, the mPFS was not reached, with a 24-month PFS rate of 52.5%. The mPFS of BRCAmut, BRCAwt, and BRCAunknown was not reached, 14.4 and 14.6m, respectively. The 24-month PFS rates were 90%, 48.4% and 37.9%, respectively. The mPFS of HRD deficient and HRD proficient were both not reached. 84.3% of patients experienced any grade TEAEs, while 17.6% experienced TEAEs of grade ≥3. TEAEs leading to treatment interruption was 36.3%, leading to dose reduction was 29.4%, leading to discontinuation was 0.98%. The most common hematological TEAEs were platelet count decreased (28.4%) while grade ≥3 TEAEs was 5.9%, white blood cell count decreased (20.6%) and neutrophil count decreased (26.5%). Non-hematologic TEAEs were nausea (31.4%), fatigue (30.4%) and insomnia (21.6%).
Conclusions
In the real world, niraparib maintenance in newly diagnosed advanced OC is effective and safe, which was consistent with previous RCT. More clinical related factors affecting prognosis will be further explored.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Tianjin Medical University Cancer Institute & Hospital.
Funding
Committee of Gynecological Oncology, Tianjin anti-cancer association.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
238P - Enfortumab-vedotin for metastatic urothelial carcinoma refractory to platinum-based chemotherapy and immune checkpoint inhibitors: A single institution experience
Presenter: Yuki Endo
Session: Poster Display
Resources:
Abstract
239P - Elevated baseline C-reactive protein is a prognostic indicator for OS in patients with metastatic non clear cell renal cell carcinoma treated with systemic therapy
Presenter: Ryuichi Mizuno
Session: Poster Display
Resources:
Abstract
240P - Efficacy and safety of first-line combination therapy with ipilimumab + nivolumab for metastatic renal cell carcinoma in a single institution in Japan
Presenter: Naoya Nagaya
Session: Poster Display
Resources:
Abstract
241P - First-line cabozantinib in metastatic renal cell carcinoma (mRCC): A real-world exploratory study from eastern India
Presenter: Tamojit Chaudhuri
Session: Poster Display
Resources:
Abstract
244P - Clinicopathologic feature and treatment outcome of metastatic non clear cell kidney cancer: A single centre experience from India
Presenter: Somnath Roy
Session: Poster Display
Resources:
Abstract
245P - The role of TGF-β in the formation of the protumor phenotype of circulating neutrophils at different stages of renal cancer
Presenter: Ilseya Myagdieva
Session: Poster Display
Resources:
Abstract
246P - Impact of renal impairment on first-line treatment in metastatic urothelial cancer
Presenter: Stephanie Wakeling
Session: Poster Display
Resources:
Abstract
247P - Adjuvant chemoradiotherapy in the management of bladder adenocarcinoma compared to multiple treatment modalities
Presenter: Othman Mohammed
Session: Poster Display
Resources:
Abstract
248P - Screening zinc homeostasis-related genes identifies metallothionein 1H (MT1H) as a potential prognostic biomarker in clear cell renal cell carcinoma (ccRCC)
Presenter: Eyad Al Masoud
Session: Poster Display
Resources:
Abstract
249P - The prognostic utility of Progestogen associated Endometrial protein (PAEP) gene expression in clear cell renal cell carcinoma (ccRCC)
Presenter: Leen Lataifeh
Session: Poster Display
Resources:
Abstract